Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

The Medical Device Co. That’s on the Cutting-Edge of Advancing Heart Disease Treatment

Back in early September , we introduced our Stockhouse audience to a unique play in the emerging medical tech space – Neovasc Inc. ( TSX: NVCN , OTCQB: NVCN , Forum ). The company develops, manufactures, and markets products for the rapidly growing cardiovascular marke...

Valeo Pharma bringing to market drug undergoing clinical trials to improve survival of COVID-19

Valeo Pharma Inc. (CSE: VPH) is a fast-growing revenue generating specialty pharmaceutical company with a strong product portfolio and a robust product pipeline. Valeo Pharma Inc. (CSE: VPH) is a fully integrated specialty pharmaceutical company focused on in-lice...

ChemoCentryx Shares Spike 300% on Phase 3 ANCA Vasculitis Trial Results

Shares of ChemoCentryx Inc. opened greater than 330% higher today after the firm reported positive topline data from its pivotal Phase 3 ADVOCATE trial of Avacopan in treatment of ANCA-associated vasculitis. After the U.S. markets closed yesterday, ChemoCentryx Inc. ...

DIAGNOS poised for parabolic move as first of new cardio AI Applications comes to market

DIAGNOS Inc. (TSX-V: ADK) (OTCQB: DGNOF) (Frankfurt: 4D4) is a Canadian-based healthcare software technology company that pioneered ' C omputer A ssisted R etinal A nalysis' (CARA), applying artificial intelligence to non-invasively test, identify, and classify patients a...

3D printing is a manufacturing game-changer

Calling all carnivores: ever thought about getting a meat printer? Of hand-crafting delectable beef steaks at home from plant proteins, that have the same texture, appearance and flavor as real meat, only without the distasteful killing part? 3D-printed steaks and chicken ...

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%

Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. Earlier today clinical-stage biopharmaceutical firm Global Blood Therapeuti...

Syros Pharma Teams Up with Global Blood Therapeutics to Fight Sickle Cell Disease

Syros Pharmaceuticals' shares rose 20% today after the firm reported that it entered into a collaboration agreement with Global Blood Therapeutics for development of therapies for sickle cell disease and beta thalassemia that could result in payments to Syros as high as $315 m...

The Revolutionary Co. That’s Breaking Through the Blood Brain Barrier

(Click image to play video) Delivery of therapeutics across the blood-brain barrier (BBB) and into the brain has been the single greatest challenge to treating hundreds of common and rare neurological diseases, including brain cancers, neurodegenerative diseases...

Nordic American Benefiting from Exceptionally Strong Tanker Market

Shares of Nordic American Tankers are trading 16.5% higher today setting a 52-week intraday high stock price as the company reported great demand for its Suezmax oil tankers. Hamilton, Bermuda-headquartered international tanker company Nordic American Tankers Ltd. (N...

Alexion's Buyout of Portola Pharmaceuticals Gets Investors' Blood Flowing

Shares of Portola Pharmaceuticals traded 130% higher after the company reported that it has received an $18 per share buyout offer from Alexion Pharmaceuticals. Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ) , which focuse...
1 2 3 4 5 6 7 8 9 10 ...